Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

5100 Xizang Glacier Company Limited
5100藏冰川有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1115)

VOLUNTARY ANNOUNCEMENT

Memorandum of Understanding with the team led by Professor Yibin FENG at the School of Chinese Medicine, The University of Hong Kong in relation to academic research collaboration on the clinical efficacy evaluation of "5100" Xizang Glacier Mineral Water in patients with hyperuricemia, as well as further research and mechanistic exploration into the potential mechanism of mineral components in mineral water in affecting uric acid metabolism and renal excretion

This announcement is voluntarily made by 5100 Xizang Glacier Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") to keep the Company's shareholders and potential investors informed of the latest business developments of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that on 27 March 2026, Carry Rich Investment Limited ("**Carry Rich**") (a wholly-owned subsidiary of the Company) and the team led by Professor Yibin FENG at the School of Chinese Medicine, The University of Hong Kong (the "**Professor Team**") (collectively referred to as the "**Parties**") entered into a Memorandum of Understanding (the "**Memorandum of Understanding**") in relation to conducting academic research collaboration on the clinical efficacy evaluation of "5100" Xizang Glacier Mineral Water on patients with hyperuricemia, as well as further research and mechanistic exploration into the potential mechanism of mineral components in the mineral water in affecting uric acid metabolism and renal excretion.

Subject Matter:

(1) Clinical Research Design and Implementation

The Professor Team shall be responsible for the scientific design of the research protocol, including randomized double-blind controlled trial protocol, inclusion and exclusion criteria, intervention protocol, follow-up procedures, outcome indicator establishment, statistical analysis plan, etc., and shall be responsible for the application for ethical review and academic supervision of research implementation.

Carry Rich shall be responsible for providing the "5100" Xizang Glacier Mineral Water products and relevant technical information required for the research, and assisting in subject recruitment support, product delivery and compliance management of product consumption in the implementation of the research.

The Parties agree to conduct the research in accordance with international clinical research standards (such as ICH-GCP) to ensure the scientific integrity, reproducibility and compliance of research data.

(2) Clinical Efficacy and Safety Evaluation

The Professor Team shall be responsible for the following matters:

(i) Conducting clinical efficacy evaluation on patients with hyperuricemia, including the detection and analysis of indicators such as changes in serum uric acid levels, target attainment rate, renal function indicators, electrolyte levels and urinary pH value; and

(ii) Monitoring adverse events during the research period and conducting safety assessment, including abdominal distension, diarrhea, edema and other potential risks, and formulating systematic safety reports.

Carry Rich may participate in discussions on research progress and assist in formulating product application strategies and health management recommendations based on research results.

(3) Data Analysis and Research Output

The Professor Team shall be responsible for statistical analysis of research data, data management and preparation of research reports, and shall form core research results available for academic publication, industry white papers and regulatory communication.

The Parties agree to jointly promote the publication and dissemination of research results in high-level international academic journals, academic conferences and industry platforms, and explore transformation paths of the results in clinical guidelines, health management products and commercial applications.

(4) Further Research and Mechanistic Exploration

Upon completion of the preliminary clinical study, the Parties may discuss the further conduct of multi-center and large-sample clinical studies to verify the generalizability and long-term safety of the research findings.

The Parties agree to explore the potential mechanism of mineral components in mineral water on uric acid metabolism and renal excretion, including studies on uric acid excretion rate, uric acid levels, metabolic pathways and relevant biomarkers. The research results may serve as scientific evidence for the formulation of precise drinking regimens for future products and personalized health management strategies.

(5) Transformation and Application

The research data may be used to support scientific promotion, substantiation of health claims and regulatory communications for the products in Chinese Mainland; Hong Kong, China; and international markets.

The Parties will explore the application of research results in digital health management platforms, artificial intelligence health assessment systems and public health education programs.

Statements regarding the Collaboration:	Statements in the Company's annual reports, disclosure documents, investor relations communications and other documents regarding the academic research collaboration shall not constitute publicity, recommendation, endorsement, warranty or efficacy commitment in respect of the Group's products, services or commercial activities, nor shall they be construed as approval or support of the Group's products or commercial activities by The University of Hong Kong, the School of Chinese Medicine of The University of Hong Kong or the Professor Team.
Term:	The Memorandum of Understanding shall take effect on 26 March 2026 and expire on 25 March 2031.
Effect:	The Memorandum of Understanding shall not be legally binding.

Professor Team Information

The Professor Team is led by Professor Yibin FENG of the School of Chinese Medicine at The University of Hong Kong and the HKUMed Centre of Integrative Medicine. He has been named in Clarivate's Highly Cited Researchers 2024, and has been ranked among the world's top 1% of scientists by Clarivate Analytics and the world's top 2% of scientists by Stanford University for consecutive years.

The Professor Team possesses strong research and transformation capabilities, with professional expertise in pharmacology, Chinese medical pharmacology, Chinese medical toxicology and Chinese internal medicine. It primarily engages in basic and clinical research on the prevention and treatment of tumors, hepatorenal diseases and diabetes using Chinese medicine, and also focuses on the research and development of health supplements, pharmaceuticals and the development and application of novel therapeutic methods in its fields of research. The academic achievements of the Professor Team are reflected in research on the material basis and molecular mechanisms of Chinese medicines for liver protection, kidney protection, hypoglycemic, anti-inflammatory, anti-oxidative and anti-tumor effects, as well as related clinical applications and substitution research on endangered Chinese medicines.

Reasons for and Benefits of the Collaboration

As a representative local enterprise in the natural drinking water industry in Xizang, the Group is dedicated to exploring the functional research of high-quality natural mineral water in the healthcare sector. This collaboration aims to integrate the traditional Chinese medicine concept of "medicine and food sharing the same origin" with modern evidence-based medical research methodologies, and conduct systematic health function research on the "5100" products, so as to provide a new research perspective for the integration of clinical treatment in Chinese medicine and daily health management. The Board considers that such collaboration will help enhance the scientific research foundation of the Group's products and accumulate experience for future product development and technological innovation in the big health sector.

General Information

The entering into of any definitive agreement is subject to further negotiations between the Parties, and there is no guarantee that the Parties will enter into any definitive agreement. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
5100 Xizang Glacier Company Limited
CHEN Di
Chairman and Non-executive Director

Hong Kong, 28 April 2026

As of the date of this announcement, the executive Directors are Mr. CHOW Wai Kit, Mr. CHENG Gwan Sing and Mr. YUE Zhiqiang, the non-executive Directors are Ms. JIANG Xiaohong, Mr. XIE Kun, Mr. WEI Zheming and Mr. CHEN Di (Chairman) and the independent non-executive Directors are Dr. ZHANG Chunlong, Mr. LO Wai Hung, Ms. LIN Ting and Ms. ZHENG Jue.